Category: Unified Patent Court
-
Erich Spangenberg’s SIM IP starts FusionLayer patent enforcement with complaint against Infoblox in UPC Hamburg LD
Last spring, Erich Spangenberg’s SIM IP completed the acquisition of FusionLayer’s cloud computing, virtual networking and internet protocol address management patent portfolio.
-
Roche’s Genentech, Organon, China’s Henlius settle major pertuzumab biosimilar litigation in U.S., UPC, NL, and Brazil (where it was most advanced)
A favorable validity decision by the Brazilian patent office and evidence preservation in the UPC contributed to this important biosimilar settlement.
-
UPC’s Paris LD takes very expansive view on access to provisional measures, but rejects ‘reservoir’ approach to original patent specification
A three-month window from a rather plaintiff-friendly starting point is significantly more than some other European courts are prepared to grant.
-
Great style: Judge Brinkman files first UPC dissenting opinion, but everyone respects each other and contributes to debate
Unlike the Court of Justice of the European Union, the UPC allows judges to file dissenting opinions. There is now an example of how constructively and respectfully this can be done.
-
UPC Court of Appeal has decided access to comparable SEP license agreements: no AEO/EEO regime, but restrictions on use in licensing
The UPC rejects restrictive rules such as Attorneys’ Eyes Only and Expert Eyes Only in order to safeguard a party’s access to justice.
-
UPC Roundup (1 week): long-arm and contempt decisions; a dozen new infringement cases; busy hearing period ahead
This is a summary of developments in and around the Unified Patent Court (UPC) in the week since our January 17, 2026 UPC Roundup. 6.2 Patent litigation summit Europe highlights measured impact of UPC on global strategy (link to detailed article) Kisaco Research’s fourth annual Patent Litigation Summit Europe concluded on January 21, 2026, after four…
-
UPC’s Mannheim LD imposes €1.72M contempt fine on Kodak for insufficient information, recall, destruction; discusses cross-border enforcement
The order is significant because of the substantial amount of the penalty as well as the olive branch it extends to the English courts.
-
“Limited” UPC impact on global pharma patent strategies, interim licenses debate, “seismic” changes at the PTAB: highlights from Patent Litigation Europe
An overwhelming consensus that life sciences companies prefer to litigate in parallel national courts rather than in the UPC, and an intense debate about the use of interim licenses over arbitration, were among the highlights of the second and third days of Kisaco’s annual Patent Litigation Europe in Amsterdam this week.
-
Efficient and elegant: UPC Paris LD disposes of BSH-based Swiss infringement claim where the patentee didn’t really believe in its granted claims
The court prioritized judicial economy, in a smart way, over one party’s weak gamble based on litigation economics.